EU vs. FDA Cosmetic Regulations — Key Differences That Affect Product Strategy

Having operated quality and regulatory functions on both sides of the Atlantic, I can say with confidence that the single most common mistake brands make when entering the EU from North America is assuming that FDA compliance translates directly into EU compliance. It does not. The two regulatory frameworks are built on different legal philosophies, use different classification criteria, and impose different pre-market obligations. Understanding these differences early — before formulation is finalised and before packaging is printed — saves significant time and cost.

This article is for regulatory affairs managers, quality directors, and executives at brands that sell or plan to sell cosmetics in both the United States and the European Union. It provides a structured comparison of the two frameworks and highlights the strategic implications of the key differences.

Regulatory Philosophy: Precautionary vs. Post-Market

The most fundamental difference between EU and US cosmetics regulation is philosophical.

The EU framework, established by Regulation (EC) No 1223/2009, operates on a precautionary principle. The Responsible Person must ensure the product is safe before it is placed on the market. This requires a documented safety assessment by a qualified assessor, a Product Information File, and a pre-market notification. The burden of demonstrating safety rests with the brand.

The US framework, governed primarily by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Fair Packaging and Labeling Act, does not require pre-market approval for cosmetics. The FDA can take action against unsafe products after they are on the market, but there is no mandatory pre-market safety assessment, no equivalent to the Product Information File, and no pre-market notification portal equivalent to the CPNP. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) has introduced new requirements — including facility registration, product listing, and adverse event reporting — but the fundamental post-market enforcement model remains.

This philosophical difference has practical consequences: a product that has been on the US market for years without incident has not, by that fact alone, met EU pre-market safety requirements.

Prohibited and Restricted Substances

The EU’s Annexes II through VI of Regulation (EC) No 1223/2009 contain the lists of prohibited substances (Annex II), restricted substances (Annex III), permitted colorants (Annex IV), permitted preservatives (Annex V), and permitted UV filters (Annex VI). The EU’s prohibited list in Annex II contains over 1,300 substances. The FDA’s list of prohibited cosmetic ingredients is considerably shorter.

This means that ingredients commonly used in US cosmetic formulations — certain preservatives, fragrances, and UV filters — may be prohibited or restricted in the EU. A formulation review against the current EU Annexes is essential before any EU launch. It is not sufficient to check only the most commonly discussed restricted substances; the full Annexes must be reviewed against the complete ingredient list.

Conversely, certain EU-permitted UV filters are not approved for use in US cosmetics. This creates a situation where a sunscreen formulated for the EU market may need reformulation for the US market, and vice versa. Brands with global ambitions need to map their formulations against both regulatory frameworks simultaneously to identify the intersection of what is permitted in both markets.

Safety Assessment Requirements

EU requirement: Before a cosmetic product is placed on the EU market, a Cosmetic Product Safety Report (CPSR) must be prepared. Part B of the CPSR — the safety assessment — must be signed by a qualified safety assessor holding a degree in pharmacy, toxicology, medicine, or a similar discipline. The assessor must evaluate the toxicological profile of all ingredients, the product’s exposure profile, and the overall safety conclusion.

US requirement: There is no equivalent mandatory pre-market safety assessment requirement under US federal law. The FDA recommends that manufacturers conduct safety testing, and the Cosmetic Ingredient Review (CIR) Expert Panel publishes safety assessments for individual ingredients, but these are not legally mandated pre-market requirements. MoCRA introduced a requirement for substantiation of safety, but the specific documentation requirements are still being developed through FDA rulemaking.

The practical implication: brands entering the EU need to budget for a CPSR for each product, and they need to identify a qualified safety assessor. This is a cost and timeline item that should be factored into EU launch planning from the outset.

Labeling: INCI vs. Common Names

EU requirement: Ingredient labeling in the EU must use International Nomenclature of Cosmetic Ingredients (INCI) names. The ingredient list must appear on the label in descending order of weight at the time of incorporation, with ingredients present at concentrations of 1% or less listed in any order after those present at more than 1%. Fragrance components do not need to be individually listed (except for 26 specified allergens above threshold concentrations), and the word “parfum” or “aroma” may be used.

US requirement: The FDA requires ingredient labeling using INCI names for retail cosmetics, which aligns with the EU on nomenclature. However, the threshold rules and allergen declaration requirements differ. The EU’s requirement to declare 26 fragrance allergens individually when present above specified thresholds (0.001% in leave-on products, 0.01% in rinse-off products) has no direct equivalent in current US federal law, though this is an area of active regulatory development.

Claims and Marketing Language

The EU’s approach to cosmetic claims is governed by Regulation (EU) No 655/2013, which establishes common criteria for claims used in relation to cosmetic products. Claims must be truthful, evidenced, honest, fair, and not misleading. The EU has published technical documents on specific claim categories — “hypoallergenic,” “dermatologically tested,” “natural” — that set out the evidence standards required.

The FDA regulates cosmetic claims primarily through the FTC Act (for advertising) and the FD&C Act (for labeling). Claims that cause a product to be regulated as a drug — claims of therapeutic effect — are treated similarly in both jurisdictions, but the boundary between a cosmetic claim and a drug claim is drawn differently, and the enforcement approach differs.

Practical Action Step

Use this comparison checklist when planning a dual-market (EU + US) product strategy:

Review the full formulation against EU Annexes II–VI and identify any ingredients that require substitution for EU compliance
Identify any EU-permitted ingredients that are not FDA-approved (particularly UV filters) if the product will also be sold in the US
Budget for a CPSR for each EU product and identify a qualified safety assessor
Review all marketing claims against both EU Regulation (EU) No 655/2013 criteria and FDA/FTC standards
Prepare separate label versions for EU (INCI, allergen declarations) and US markets
Confirm EU Responsible Person appointment and CPNP notification plan
Confirm MoCRA compliance obligations (facility registration, product listing) for US market

Global product strategy requires simultaneous compliance mapping across both frameworks. Consult a qualified EU regulatory expert — and a US regulatory specialist — before finalising formulations and claims for dual-market launches.

Care Europe provides EU regulatory consulting for brands managing global product portfolios, including EU-US compliance gap analysis and market entry strategy. Contact us to discuss your product strategy.

EU vs. FDA Cosmetic Regulations — Key Differences That Affect Product Strategy